The rapid diagnosis of Mycoplasma pneumonia using in situ hybridization on clinical samples.
Ann Diagn Pathol
; 63: 152100, 2023 Apr.
Article
in English
| MEDLINE | ID: covidwho-2243832
ABSTRACT
The microbiological etiology of seasonal upper respiratory illnesses in the United States is dominated by viruses, including influenza A, B, respiratory syncytial virus, and SARS-CoV2. Mycoplasma pneumonia, treatable with antibiotics, can also cause upper respiratory symptoms and is typically associated with about 15 % of cases. There is no clinical or radiologic finding diagnostic of Mycoplasma pneumonia infection and PCR-based testing is not routinely used in the clinical setting. Further, the bacteria grows slowly in culture and the diagnostic IgM response will take days after the onset of infection. Thus, a rapid diagnostic test for Mycobacterium pneumonia infection is needed. This study documented two cases of Mycoplasma pneumonia infection of the upper respiratory system using in situ hybridization in a series of over 20 patients who were being tested for SARS-CoV2 infection. The respiratory secretions were placed on a glass slide, fixed in 10 % buffered formalin, and then tested using a Mycoplasma pneumonia probe. The high bacterial number associated with acute infection allowed for straightforward detection by in situ hybridization in a few hours. Antibiotic therapy led to rapid resolution of the symptoms. This highlights the ability of standard in situ hybridization as a rapid diagnostic test for Mycoplasma pneumonia in the clinical setting.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Mycoplasma
/
COVID-19
Type of study:
Diagnostic study
/
Etiology study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Ann Diagn Pathol
Journal subject:
Pathology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS